CL2011002664A1 - Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. - Google Patents

Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Info

Publication number: CL2011002664A1
Authority: CL; Chile
Prior art keywords: vector; nucleic acid; procedure; cxcr4; study
Prior art date: 2009-04-29

Application number

CL2011002664A

Other languages

English (en)

Inventor

Christine Klinguer-Hamour

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-29

Filing date

2011-10-26

Publication date

2012-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002664(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-26 Application filed by Pf Medicament filed Critical Pf Medicament

2012-12-14 Publication of CL2011002664A1 publication Critical patent/CL2011002664A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Virology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL2011002664A 2009-04-29 2011-10-26 Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. CL2011002664A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17368009P	2009-04-29	2009-04-29
EP09159076A EP2246364A1 (en)	2009-04-29	2009-04-29	Anti CXCR4 antibodies for the treatment of HIV

Publications (1)

Publication Number	Publication Date
CL2011002664A1 true CL2011002664A1 (es)	2012-12-14

Family

ID=41060014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011002664A CL2011002664A1 (es)	2009-04-29	2011-10-26	Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Country Status (25)

Country	Link
US (3)	US9090686B2 (es)
EP (2)	EP2246364A1 (es)
JP (1)	JP5800802B2 (es)
KR (1)	KR20120039525A (es)
CN (1)	CN102459343B (es)
AU (1)	AU2010243526B2 (es)
BR (2)	BRPI1011540A2 (es)
CA (1)	CA2759989A1 (es)
CL (1)	CL2011002664A1 (es)
CO (1)	CO6390114A2 (es)
ES (1)	ES2534313T3 (es)
GE (1)	GEP20146181B (es)
HU (1)	HUE025083T2 (es)
IL (1)	IL215919A0 (es)
MA (1)	MA33285B1 (es)
MX (1)	MX2011011285A (es)
MY (1)	MY155400A (es)
NZ (1)	NZ596712A (es)
PL (1)	PL2424897T3 (es)
RU (1)	RU2573902C2 (es)
SG (1)	SG175353A1 (es)
TN (1)	TN2011000534A1 (es)
UA (1)	UA107929C2 (es)
WO (1)	WO2010125162A1 (es)
ZA (1)	ZA201108330B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2371863A1 (en) *	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer
CA2814908A1 (en) *	2010-10-27	2012-05-03	Pierre Fabre Medicament	Antibodies for the treatment of hiv
DK3252076T3 (da)	2011-01-14	2019-12-02	Univ California	Diagnostisk anvendelse af antistoffer mod ror-1-protein
US20140120555A1 (en) *	2011-06-20	2014-05-01	Pierre Fabre Medicament	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2723380B1 (en)	2011-06-24	2019-08-21	Stephen D. Gillies	Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) *	2011-07-29	2014-03-19	Pf Medicament	Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
ES2949060T3 (es)	2013-12-02	2023-09-25	Univ Columbia	Mejora de la potencia y amplitud de anticuerpos neutralizantes del VIH-1 mediante el anclaje de receptores celulares utilizando anticuerpos biespecíficos con arquitectura nativa
US10308707B2 (en)	2013-12-02	2019-06-04	Aaron Diamond Aids Research Center	Bispecific HIV-1-neutralizing antibodies
UA125819C2 (uk)	2015-12-15	2022-06-15	Гіліад Сайєнсіз, Інк.	ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
KR102379464B1 (ko)	2016-06-20	2022-03-29	키맵 리미티드	항-pd-l1 항체
JP7009517B2 (ja)	2017-06-21	2022-01-25	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US11180575B2 (en)	2018-12-28	2021-11-23	Corn Products Development, Inc.	Thermally inhibited starch and process for making
US20210024873A1 (en)	2018-03-27	2021-01-28	Bristol-Myers Squibb Company	Real-time monitoring of protein concentration using ultraviolet signal
CN111214650A (zh) *	2018-11-23	2020-06-02	广州溯原生物科技有限公司	一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (en)	2019-02-24	2020-08-27	Bristol-Myers Squibb Company	Methods of isolating a protein
JP7645198B2 (ja)	2019-05-23	2025-03-13	ブリストル－マイヤーズスクイブカンパニー	細胞培養培地をモニターする方法
EP4090433A4 (en) *	2020-01-16	2024-02-14	Caerus Therapeutics, Inc.	HUMANIZED ANTIBODIES SPECIFIC FOR MYELOMA AND OVARIAL CARCINOMA CELLS
US20230374064A1 (en)	2020-10-05	2023-11-23	Bristol-Myers Squibb Company	Methods for concentrating proteins
JP2025509274A (ja)	2022-03-09	2025-04-11	ブリストル－マイヤーズスクイブカンパニー	治療用タンパク質の一過性発現
US12006353B2 (en) *	2022-07-25	2024-06-11	Long Chen	Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof
CN115724993A (zh) *	2022-07-26	2023-03-03	陈龙	Scfv蛋白的应用、car基因表达载体、car-t细胞及应用
EP4606385A1 (en)	2022-10-18	2025-08-27	Meiji Seika Pharma Co., Ltd.	Therapeutic agent for t cell tumor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
DE69126301T2 (de) *	1990-11-27	1998-01-02	Biogen, Inc., Cambridge, Mass.	Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
SG41929A1 (en) *	1992-09-25	1997-08-15	Commw Scient Ind Res Org	Target binding polypeptide
EP0854918A1 (en) *	1996-01-30	1998-07-29	The National Institutes of Health	Cells expressing both human cd4 and cxcr4
AU2841101A (en) *	1999-12-08	2001-06-18	Novartis Ag	Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
US7321026B2 (en) *	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
US20040093621A1 (en) *	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
MXPA06000252A (es) *	2003-06-30	2006-12-15	Bio Technology General Israel	Anticuerpos y usos de los mismos.
US20080039428A1 (en) *	2006-06-29	2008-02-14	Panacos Pharmaceuticals, Inc.	Antiretroviral combination therapy
KR20090052358A (ko) *	2006-09-29	2009-05-25	에프. 호프만-라 로슈 아게	Ｃｃｒ5 에 대한 항체 및 이의 용도
WO2008105560A1 (ja) *	2007-02-27	2008-09-04	Forerunner Pharma Research Co., Ltd.	抗grp78抗体を有効成分として含む医薬組成物
EA201071300A1 (ru) *	2008-05-14	2011-06-30	Эли Лилли Энд Компани	Антитела к cxcr4
EP2172485A1 (en) *	2008-10-01	2010-04-07	Pierre Fabre Medicament	Novel anti CXCR4 antibodies and their use for the treatment of cancer
US20120276092A1 (en) *	2009-10-29	2012-11-01	Jinquan Luo	Antibody Glycosylation Variants
EP2371863A1 (en) *	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer

2009
- 2009-04-29 EP EP09159076A patent/EP2246364A1/en not_active Withdrawn
2010
- 2010-04-29 ES ES10721376.1T patent/ES2534313T3/es active Active
- 2010-04-29 MY MYPI2011005123A patent/MY155400A/en unknown
- 2010-04-29 NZ NZ596712A patent/NZ596712A/xx not_active IP Right Cessation
- 2010-04-29 MX MX2011011285A patent/MX2011011285A/es active IP Right Grant
- 2010-04-29 CA CA2759989A patent/CA2759989A1/en not_active Abandoned
- 2010-04-29 HU HUE10721376A patent/HUE025083T2/en unknown
- 2010-04-29 MA MA34368A patent/MA33285B1/fr unknown
- 2010-04-29 BR BRPI1011540-4A patent/BRPI1011540A2/pt not_active IP Right Cessation
- 2010-04-29 PL PL10721376T patent/PL2424897T3/pl unknown
- 2010-04-29 AU AU2010243526A patent/AU2010243526B2/en not_active Ceased
- 2010-04-29 UA UAA201114024A patent/UA107929C2/ru unknown
- 2010-04-29 EP EP10721376.1A patent/EP2424897B1/en active Active
- 2010-04-29 JP JP2012507772A patent/JP5800802B2/ja not_active Expired - Fee Related
- 2010-04-29 RU RU2011148077/10A patent/RU2573902C2/ru not_active IP Right Cessation
- 2010-04-29 CN CN201080028221.XA patent/CN102459343B/zh not_active Expired - Fee Related
- 2010-04-29 WO PCT/EP2010/055863 patent/WO2010125162A1/en not_active Ceased
- 2010-04-29 KR KR1020117027755A patent/KR20120039525A/ko not_active Ceased
- 2010-04-29 GE GEAP201012429A patent/GEP20146181B/en unknown
- 2010-04-29 SG SG2011078334A patent/SG175353A1/en unknown
- 2010-10-27 US US12/913,300 patent/US9090686B2/en not_active Expired - Fee Related
2011
- 2011-10-21 TN TNP2011000534A patent/TN2011000534A1/en unknown
- 2011-10-25 IL IL215919A patent/IL215919A0/en unknown
- 2011-10-26 CL CL2011002664A patent/CL2011002664A1/es unknown
- 2011-10-27 BR BR112013009984A patent/BR112013009984A2/pt not_active IP Right Cessation
- 2011-10-27 US US13/823,182 patent/US20130174288A1/en not_active Abandoned
- 2011-11-14 ZA ZA2011/08330A patent/ZA201108330B/en unknown
- 2011-11-25 CO CO11162444A patent/CO6390114A2/es active IP Right Grant
2015
- 2015-06-22 US US14/745,866 patent/US20160031995A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UA107929C2 (en)	2015-03-10
EP2246364A1 (en)	2010-11-03
EP2424897A1 (en)	2012-03-07
AU2010243526B2 (en)	2015-02-12
NZ596712A (en)	2013-10-25
JP5800802B2 (ja)	2015-10-28
CN102459343B (zh)	2015-09-16
US20160031995A1 (en)	2016-02-04
KR20120039525A (ko)	2012-04-25
CO6390114A2 (es)	2012-02-29
ZA201108330B (en)	2012-09-26
BRPI1011540A2 (pt)	2019-04-30
HUE025083T2 (en)	2016-02-29
TN2011000534A1 (en)	2013-05-24
JP2012525129A (ja)	2012-10-22
BR112013009984A2 (pt)	2017-07-18
CA2759989A1 (en)	2010-11-04
US9090686B2 (en)	2015-07-28
US20130174288A1 (en)	2013-07-04
HK1165813A1 (en)	2012-10-12
ES2534313T3 (es)	2015-04-21
SG175353A1 (en)	2011-11-28
PL2424897T3 (pl)	2015-07-31
MY155400A (en)	2015-10-15
GEP20146181B (en)	2014-10-27
IL215919A0 (en)	2011-12-29
RU2011148077A (ru)	2013-06-10
WO2010125162A1 (en)	2010-11-04
CN102459343A (zh)	2012-05-16
US20110088104A1 (en)	2011-04-14
AU2010243526A1 (en)	2011-12-22
MA33285B1 (fr)	2012-05-02
MX2011011285A (es)	2012-01-20
RU2573902C2 (ru)	2016-01-27
EP2424897B1 (en)	2015-01-07

Similar Documents

Publication	Publication Date	Title
CL2011002664A1 (es)	2012-12-14	Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.
CL2013002044A1 (es)	2014-05-09	Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
CL2014003110A1 (es)	2015-06-19	Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
CL2014000291A1 (es)	2014-08-08	Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer.
CL2013000868A1 (es)	2014-01-24	Anticuerpo aislado que se une al complejo i del citomegalovirus humano (hcmv) o al gh de hcmv; acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para tratar, inhibir o prevenir la infeccion por hcmv.
CL2015000665A1 (es)	2015-06-26	Compuesto análogo de glucagón útil para prevenir ganancia de peso o promover pérdida de peso; ácido nucleico que lo codifica; vector; célula huésped; kit; y procedimiento de producción.
BR112012015740A2 (pt)	2017-04-25	anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2007001488A1 (es)	2008-01-04	Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2011002003A1 (es)	2012-05-25	Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2013000545A1 (es)	2014-09-26	Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune.
PH12015502553A1 (en)	2017-04-10	Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112013032434A2 (pt)	2016-09-06	restauração dentária, método para sua produção e vidro cerâmico
MX2017008186A (es)	2018-02-09	Anticuerpos humanos para la hemaglutinina de influenza.
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2013001121A1 (es)	2014-03-07	Acido ribonucleico interferente; polinucleotido que lo codifica; construccion de adn que lo codifica; celula huesped; composicion que lo comprende; y su uso para la prevencion y/o control de la infestacion por plaga.
BR112012022210A2 (pt)	2017-09-05	anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
NI201100172A (es)	2012-01-10	Inhibidores de la replicación del virus de la hepatitis c
CO6280490A2 (es)	2011-05-20	4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
MX386750B (es)	2025-03-19	MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
CL2008000820A1 (es)	2008-08-22	Anticuerpo aislado o fragmentos funcionales con capacidad para neutralizar cepas hiv; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir un anticuerpo; uso del anticuerpo para el tratamie
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112015010817A2 (pt)	2017-11-28	anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
DOP2012000250A (es)	2013-02-15	COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
CL2009000862A1 (es)	2009-08-14	Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
CL2012002415A1 (es)	2013-08-23	Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.